AMBALALSA vs SUDEEPPHRM: Stock Comparison

Ambalal Sarabhai Enterprises Ltd vs Sudeep Pharma LtdUpdated 20 Aug 26, 4:08 PM ISTNSE & company filings

Sudeep Pharma Ltd is the larger company by market capitalisation. Ambalal Sarabhai Enterprises Ltd shows a lower P/E, while Sudeep Pharma Ltd shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AMBALALSA leads 2; SUDEEPPHRM leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AMBALALSASUDEEPPHRM

Valuation lens

What price are you paying?

Market CapContext only
₹338 Cr
₹12,743 Cr
P/E RatioAMBALALSA has the lower reading
27.1x
69.8x
P/B RatioAMBALALSA has the lower reading
2.22x
14.45x
EPSSUDEEPPHRM has the higher reading
₹2.32
₹16.8
Book ValueContext only
₹20.7
₹78.2
Dividend YieldSUDEEPPHRM has the higher reading
0%
0.14%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUDEEPPHRM is the larger company
₹12,743 Cr vs ₹338 Cr
P/E Ratio
AMBALALSA has a lower P/E
27.1x vs 69.8x
P/B Ratio
AMBALALSA has a lower P/B
2.22x vs 14.45x
EPS
SUDEEPPHRM has higher earnings per share
₹16.8 vs ₹2.32
Dividend Yield
SUDEEPPHRM has a higher dividend yield
0.14% vs 0%
Qtr Sales Growth
SUDEEPPHRM has stronger quarterly sales growth
26.7% vs 1.05%
Qtr Profit Growth
SUDEEPPHRM has stronger quarterly profit growth
31.6% vs 13.4%
ROE
SUDEEPPHRM has a higher ROE
25.2% vs 12.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricAMBALALSASUDEEPPHRM
Live Price₹47.74₹1,127.2
Day Change3.07%-0.35%
Volume2.46 L1.5 L
52-Week High₹49.98₹1,180
52-Week Low₹30.15₹524.05
Distance from 52W High-4.48%-4.47%

Valuation

MetricAMBALALSASUDEEPPHRM
Market Cap₹338 Cr₹12,743 Cr
P/E Ratio27.1x69.8x
P/B Ratio2.22x14.45x
EPS₹2.32₹16.8
Book Value₹20.7₹78.2
Dividend Yield0%0.14%

Growth

MetricAMBALALSASUDEEPPHRM
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth1.05%26.7%
Qtr Profit Growth13.4%31.6%

Profitability & Leverage

MetricAMBALALSASUDEEPPHRM
ROE12.4%25.2%
ROCE11.5%28.2%
Net Margin8.8%27.14%
Operating Margin5.82%34.5%
Debt to Equity0.36x0.17x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAMBALALSASUDEEPPHRM
Promoter Holding31.36%76.15%
FII Holding0%1.81% 0.26 pp
DII Holding0.01%15.65% 2.46 pp
Public Holding68.64%6.39% 2.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ambalal Sarabhai Enterprises Ltd and Sudeep Pharma Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.